EP 1094781 A1 20010502 - COMPOSITIONS FOR RAPID AND NON-IRRITATING TRANSDERMAL DELIVERY OF PHARMACEUTICALLY ACTIVE AGENTS AND METHODS FOR FORMULATING SUCH COMPOSITIONS AND DELIVERY THEREOF
Title (en)
COMPOSITIONS FOR RAPID AND NON-IRRITATING TRANSDERMAL DELIVERY OF PHARMACEUTICALLY ACTIVE AGENTS AND METHODS FOR FORMULATING SUCH COMPOSITIONS AND DELIVERY THEREOF
Title (de)
ZUSAMMENSETZUNGEN FÜR DIE SCHNELLE UND NICHT-IRRITIERENDE TRANSDERMALE VERABREICHUNG VON PHARMAZEUTIKA AND VERFAHREN ZUR FORMULIERING DAVON UND IHREN VERABREICHUNG
Title (fr)
COMPOSITIONS D'ADMINISTRATION TRANSDERMIQUE RAPIDE ET NON IRRITANTE D'AGENTS PHARMACEUTIQUES ACTIFS ET METHODES POUR LA FORMULATION DE CES COMPOSITIONS ET LEUR ADMINISTRATION
Publication
Application
Priority
- US 9915297 W 19990707
- US 9191098 P 19980707
Abstract (en)
[origin: US7267829B2] A transdermal delivery system (TDS)for use in treatment of living bodies may be applied as an open (liquid, gel) or closed (patch) article. The TDS is composed of a particular active agent which dictates an associated selection of certain solvents, solvent modifiers, solute modifiers and skin stabilizers with which the medicament forms a true solution that rapidly crosses the skin barrier. The associated selection of the particular solvents, solvent modifiers, solute modifiers and skin stabilizers is based on a balancing of the molecular properties of all the components against the molecular properties of all the components plus the particular active agent. The TDS may also include a source of cellular energy to induce CAMP or cGMP. The TDS improves delivery of active agents having a molecular weight greater than 340 Daltons and increases dosage above 0.25 mg/day for such active agents.
IPC 1-7
IPC 8 full level
A61K 9/00 (2006.01); A61K 47/10 (2006.01); A61K 8/00 (2006.01); A61K 8/31 (2006.01); A61K 8/33 (2006.01); A61K 8/34 (2006.01); A61K 8/36 (2006.01); A61K 8/37 (2006.01); A61K 8/41 (2006.01); A61K 8/46 (2006.01); A61K 8/49 (2006.01); A61K 8/60 (2006.01); A61K 8/96 (2006.01); A61K 8/97 (2006.01); A61K 8/98 (2006.01); A61K 8/99 (2006.01); A61K 36/00 (2006.01); A61K 36/232 (2006.01); A61K 36/324 (2006.01); A61K 36/53 (2006.01); A61K 36/74 (2006.01); A61K 47/12 (2006.01); A61K 47/46 (2006.01); A61L 15/44 (2006.01); A61P 17/00 (2006.01); A61Q 19/00 (2006.01)
CPC (source: EP US)
A61K 9/0014 (2013.01 - EP US); A61K 36/232 (2013.01 - EP US); A61K 36/324 (2013.01 - EP US); A61K 36/53 (2013.01 - EP US); A61K 36/74 (2013.01 - EP US); A61K 36/752 (2013.01 - EP US); A61K 47/10 (2013.01 - EP US); A61K 47/12 (2013.01 - EP US); A61P 17/00 (2018.01 - EP)
C-Set (source: EP US)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0001351 A1 20000113; AT E399565 T1 20080715; AU 4972599 A 20000124; CA 2336682 A1 20000113; CA 2336682 C 20061010; DE 69939019 D1 20080814; DK 1094781 T3 20081103; EP 1094781 A1 20010502; EP 1094781 A4 20070117; EP 1094781 B1 20080702; ES 2310042 T3 20081216; JP 2002519366 A 20020702; MX PA00012844 A 20040521; PT 1094781 E 20081008; US 2003104040 A1 20030605; US 2004202709 A1 20041014; US 6444234 B1 20020903; US 6787152 B2 20040907; US 7267829 B2 20070911
DOCDB simple family (application)
US 9915297 W 19990707; AT 99933731 T 19990707; AU 4972599 A 19990707; CA 2336682 A 19990707; DE 69939019 T 19990707; DK 99933731 T 19990707; EP 99933731 A 19990707; ES 99933731 T 19990707; JP 2000557798 A 19990707; MX PA00012844 A 19990707; PT 99933731 T 19990707; US 38109500 A 20000511; US 7449702 A 20020211; US 83141604 A 20040423